Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond
The development of antibody-based therapies has transformed the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. More recently, HER2-directed antibody-drug conjugates (ADCs) have demonstrated efficacy in HER2-negative breast cancer patients who had a certain level...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.24.183 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|